New Horizons in Kidney Transplant: Preventing Antibody-Mediated Rejection in Sensitized Patients

Size: px

Start display at page:

Download "New Horizons in Kidney Transplant: Preventing Antibody-Mediated Rejection in Sensitized Patients"

Christine Tyler
5 years ago
Views:

1 New Horizons in Kidney Transplant: Preventing Antibody-Mediated Rejection in Sensitized Patients Denis Glotz, MD, PhD Saint-Louis Hospital Paris, France Robert A. Montgomery, MD, DPhil, FACS The Johns Hopkins Hospital Baltimore, Maryland In conjunction with the 2014 World Transplant Congress, July 26-31, 2014, in San Francisco, California.

2 Faculty Disclosures Denis Glotz, MD, PhD, has a financial interest/relationship or affiliation in the form of: Grant/Research Support from CSL Behring and Thermo Fisher Scientific Inc. Speakers Bureau participant with Alexion; F. Hoffmann-Roche; Sanofi; and Thermo Fisher Scientific Inc. This activity has been jointly sponsored by the University of New Mexico School of Medicine, Office of Continuing Medical Education, and PVI, PeerView Institute for Medical Education. This activity is supported by an unrestricted educational grant from Alexion Pharmaceuticals. This symposium is not part of the WTC official educational program and the sessions and content are not endorsed by WTC.

3 Faculty Disclosures Robert A. Montgomery, MD, DPhil, FACS, has a financial interest/relationship or affiliation in the form of: Consultant for ipierian Inc. Grant/Research Support from Alexion; Genzyme Corporation, a Sanofi company; and ViroPharma Incorporated, a wholly owned subsidiary of Shire, PLC. Scientific Advisory for Astellas Pharma US, Inc.; and Gambro. This activity has been jointly sponsored by the University of New Mexico School of Medicine, Office of Continuing Medical Education, and PVI, PeerView Institute for Medical Education. This activity is supported by an unrestricted educational grant from Alexion Pharmaceuticals. This symposium is not part of the WTC official educational program and the sessions and content are not endorsed by WTC.

4 Presentation 1: Antibody-Mediated Rejection: Clinical Phenotypes Photo Pending Denis Glotz, MD, PhD Saint-Louis Hospital Paris, France

5 Rejection Is an Antibody Process 1 CDC: complement-dependent cytotoxicity; Ig: immunoglobulin. 1. Taylor CJ et al. Transplantation. 1989;48:

6 Hyperacute Rejection 1 1. Courtesy of Denis Glotz, MD, PhD.

7 Patterns of Gene Expression 1 Rejection A : 50% graft loss Rejection B: Toxicity; infection Rejection C: CAN Rejection D: Normal CAN: chronic allograft nephropathy rejection type III. 1. Sarwal M et al. N Engl J Med. 2003;349:

8 Patterns of Gene Expression 1 AR: acute rejection; HLA: human leukocyte antigen: IL: interleukin; IFN: interferon; NK: natural killer. 1. Sarwal M et al. N Engl J Med. 2003;349:125-38

Laboratory Diagnosis of DSA: Luminex Assay 1 High sensitivity and specificity for HLA antibody detection Detects many more antibodies than are

9 Laboratory Diagnosis of DSA: Luminex Assay 1 High sensitivity and specificity for HLA antibody detection Detects many more antibodies than are observed by the less sensitive and less specific CDC assay AMR: antibody-mediated rejection. 1. Chen G et al. Methods Mol Biol. 2013;1034:

10 Immunohistochemistry Versus Immunofluorescence 1 Kidney IF IHC IFV: immunofluorescence; IH: immunohistochemistry:. 1. Courtesy of Dominique Nochy.

11 AMR in Renal Transplant 1 Histological lesions ATN PTC, glomerulopathy, thrombosis Arteritis C4d+ DSA ATN: acute tubular necrosis; DSA: donor-specific antibody; PTC: peritubular capillaritis.. 1. Racusen LC et al. Am J Transplant Jun;3(6):

12 C4d Positivity in Various Treatment Centers Authors Biopsies/Pts Indication C4d+ (% Pt) Feucht /93 Renal failure 46% Lederer /218 Renal failure 46%-72% Regele /61 Renal failure 51% Bohmig /58 Renal failure 28% Nickeleit /265 Renal failure 35% Herzenberg /93 Rejection 37% Mauiyyedi /67 Renal failure 30% Regele /213 Renal failure 34% Sund /37 Protocol 30% Koo /48 Protocol 13% 1. Courtesy of Denis Glotz, MD, PhD.

13 AMR in KTRs: Biopsies for Cause 1 KTR: kidney transplant recipient. 1. Lefaucheur C et al. J Am Soc Nephrol :

14 AMR: An Evolutive Process 1 Bringing together the pieces of the puzzle Quantitation DSA pre-tx graft survival Histology and graft survival? MFI: mean fluorescence intensity. 1. Lefaucheur C et al. J Am Soc Nephrol :

15 Subclinical AMR Function Pathology Usefulness of Abs/screening biopsies+++ Ab: antibody.

Defining Subclinical AMR 1-3 Patient in a steady state:

Evidence for Ab action in PTC: C4d+ Evidence for serologic

Am J Transplant. 2007;7:2124-2132. 2. Haas M et al.

16 Defining Subclinical AMR 1-3 Patient in a steady state: Stable GFR Evidence for Ab injury: glomerulitis+/ptc+ Evidence for Ab action in PTC: C4d+ Evidence for serologic Ab: DSA+ GFR: glomerular filtration rate. 1. Gloor J et al. Am J Transplant. 2007;7: Haas M et al. Am J Transplant. 2007;7: Lerut E at al. Translantation 2007;83:

17 Anti-HLA Antibodies and Late Allograft Loss 1 GFR: glomerular filtration rate. 1. Lee PC et al. Transplantation ;74(8):

Control group never developed antibodies.

18 Proteinuria is the Hallmark of Glomerular Injury 1 The relationship between HLA Ab and proteinuria in KTR developing DSA and NDSA a Control group never developed antibodies. NDSA: non donor-specific antibodies. 1. Fotheringham J et al. Transplantation ;91(9):991-6.

19 It All Starts With Proteinuria 1 egfr: estimated glomerular filtration rate. 1. Fotheringham J et al. Transplantation. 2011;15:

20 Presence of DSA Frequent in Late Biopsies For Cause 1 DSA distribution in pts undergoing late biopsies for clinical indication PRA: panel-reactive antibody. 1. Hidalgo LG et al. Am J Transplant. 2009;9(11):

novo DSA versus those without Time From Transplant,

21 Development of De Novo DSA Is Associated With Allograft Loss 1 Graft survival of patients with de novo DSA versus those without Time From Transplant, y 1. Wiebe C et al. Am J Transplant. 2012;12:

Nature History of Subclinical AMR 1 Evolution of chronic lesions in DSA+ patients according to time of screening biopsy a CG a Mean +/- SEM, data including nine additional screening

22 Nature History of Subclinical AMR 1 Evolution of chronic lesions in DSA+ patients according to time of screening biopsy a CG a Mean +/- SEM, data including nine additional screening biopsies performed at 3 y. CG: chronic glomerulopathy; IF: interstitial fibrosis; SEM: standard error of measurement; TA: tubular atrophy. 1. Loupe A et al. Am J Transplant. 2009; 9:

23 AMR Is the Leading Cause of Late Graft Failure 1 PVN 7% Missing data 5% Medical conditions 10% GN 13% ABMR AMR 47% Nonadherent 48% Adherent 52% Mixed 5% Probable AMR 13% 65% of subsequent failures could be attributed to AMR, probable AMR, or mixed; 48% were nonadherent GN: glomerulonephritis; PVN: polyomavirus nephropathy. 1. Sellarés J et al. Am J Transplant. 2012;12:

24 The Spectrum of Clinical Phenotypes 1 Hyperacute Acute Caused when high titers of DSA are present Happens within min to d Rare (due to crossmatching) Occurs in 5%-7% of KTRs Causes 20%-48% of acute-rejection episodes in presensitized crossmatched patients Manifests over days as a result of DSA Chronic Antibody mediated Characteristically seen as TG on kidney biopsy TG prevalence in protocol biopsies varies from 5% at 1 y to 20% at 5 y Manifestations Early stages: asymptomatic Advanced stages: nephrotic-range proteinuria Hypertension Allograft dysfunction; progression may be fairly rapid TG: transplant glomerulopathy. 1. Puttarajappa C et al. J Transplant.2012;2012:193724

25 80 DSA+ KTRs: 157 Protocol Biopsies 1 C4d status fluctuates during the first-year post-transplant, reflecting a dynamic process C4d = 3 C4d = 2 C4d = 1 C4d = 0 1. Loupy A et al. Am J Transplant. 2009;9:

26 Is Complement Necessary for Antibody-Mediated Lesions? 1 Specificity/sensitivity/positive predictive and negative predictive values for C4d Sensitivity = 0.69 Specificity = 0.83 PPV = 0.93 NPV = 0.44 C4d+ (n = 90) KTRs with preformed DSA (n = 80) Protocol biopsies at 3-mo and 1-y post-transplant (n = 157) C4d- (n = 67) Microvascular inflammation + (n = 84) Microvascular inflammation (n = 6) Microvascular inflammation + (n = 37) NPV: negative predictive value; PPV: positive predictive value. 1. Loupy A et al. Am J Transplant. 2011;11: Microvascular inflammation (n = 30)

27 Banff 2013: Inclusion of C4d- AMR and Antibody-Associated Arterial Lesions Full-blown acute AMR (acute AMR type 1) Acute AMR without evident complement deposition (acute AMR type 2) C4d-positive subclinical AMR (subclinical AMR type 1) Subclinical AMR without evident complement deposition (subclinical AMR type 2) C4d-positive chronic AMR (chronic AMR type 1) Chronic AMR without evident complement deposition (chronic AMR type 2) C4d staining without histologic evidence of rejection 1. Haas M et al. Am J Transplant. 2014;14:

28 Diagnostic Criteria for Acute AMR in KTR: Clinical Phenotypes: C4d+ vs C4d- 1 C4d+ Serological evidence DSA present Immunopathic evidence IF: diffuse-positive C4d in PTC IHC: diffuse of focal-positive C4d in PTC Histological evidence ATN-like changes and/or PTC and/or Glomerulitis and/or Thrombotic microangiopathy and/or Arterial fibrinoid necrosis and No evidence of chronic capillary injury a C4d- Serological evidence DSA present Immunopathic evidence Negative C4d staining and Endothelial activation, detected by increased mrna expression of endothelial genes and/or Evidence for glomerular and/or capillary endothelial cycling Histological evidence PTC and/or Glomerulitis and/or Thrombotic microenglopathy and/or Arterial fibrinoid necrosis and No evidence of chronic capillary injury a a Reduplication and/or multilayering of glomerular and PTC basement membranes. ATN: acute tubular necrosis; DSA: donor-specific antigen; IHC: Immunohistochemistry; IF: interstitial fibrosis; KTR: kidney transplant recipient; PTC: peritubular capillaritis.. 1. Mengel M et al. Transpl Int. 2012;25:

29 Diagnostic Criteria for Chronic AMR in KTR: Clinical Phenotypes: C4d+ vs C4d- 1 C4d+ C4d- Serological evidence DSA present Immunopathic evidence IF: diffuse-positive C4d in PTC IHC: diffuse of focal-positive C4d in PTC Histological evidence Transplant glomerulopathy and/or PTC basement membrane multilamination and/or IF with tubular atrophy and/or Fibrous intimal thickening of arteries Glomerulitis and/or capillaritis may accompany 1. Mengel M et al. Transpl Int. 2012;25: Serological evidence DSA present Immunopathic evidence Negative C4d staining and Endothelial activation, detected by increased mrna expression of endothelial genes and/or Evidence for glomerular and/or capillary endothelial cycling Histological evidence Transplant glomerulopathy and/or PTC basement membrane multilamination and/or IF with tubular atrophy and/or Fibrous intimal thickening of arteries Glomerulitis and/or capillaritis may accompany

30 Low Positive Predictive Value of DSA for AMR 1 Specificity/sensitivity/PPV/NPV for AMR Method N PPV Sensitivity (%) Specificity (%) CXM DSA ELISA DSA Luminex CXM: crossmatch. 1. Courtesy of Denis Glotz, MD, PhD.

specificity, and functional potential SAB:

31 Solid-Phase Assays for Antibodies 1 Complement-fixing C1q assay on the HLA SAB that combines sensitivity, specificity, and functional potential SAB: single-antigen bead. 1. Chen G et al. Hum Immunol. 2011;72:

32 Post Treatment DSA: Outcomes 1 DSA+/C1q+ = higher risk of graft loss 1. Loupy A et al. N Engl J Med. 2013;369:

33 Presentation 2: The Role of Complement Inhibition in Preventing and Treating AMR Robert A. Montgomery, MD, DPhil, FACS The Johns Hopkins Hospital Baltimore, Maryland

34 AMR: Pathogenesis of the Humoral Immune Response 1 Plasmablasts Plasma cells HLA antibody Clonal expansion T cell Complement activation Memory B cells LLPC Bone marrow LLPC: long-lived plasma cell. 1. Montgomery RA et al. Semin Immunol. 2011;23: Coagulative necrosis

35 AMR: Therapeutic Targets for Interrupting the Humoral Immune Response 1 Proteosomal Inhibitors HLA antibody IVIg and Plasmapheresis Anti-CD20 Clonal expansion Plasmablasts Plasma cells Splenectomy T-Cell ATG, Steroids Memory B cells Complement Inhibitors Complement Activation LLPC Bone marrow ATG: anti-thymocyte globulin; IVIg: intravenous immunoglobulin 1. Montgomery et al. Seminars in Immunology : Coagulative necrosis

36 Does Rituximab Prevent An Anamnestic Response 1 Made Antibody to Tetramer Antigen b Post-Transplant Antibody Production to Antigens With Elevated B-Cell Frequencies a Treated With Rituximab Yes No Yes 0 13 Χ 2 1= 16.2 P = No 10 3 Tetramers used to determine the frequencies of B cells with HLA specificities that are not producing soluble antibody Tetramers are available only for a limited number of HLA molecules a There was not detectable antibody to the tested tetramer antigen prior to transplantation. b Made antibody to the tetramer antigen after transplantation. 1. Zachary AA et al. Transplantation. 2013;95:

Placebo-Controlled, Randomized Trial of SOC ± Rituximab For Treatment of AMR 1 Primary endpoint: a composite criterion (graft loss or absence of improvement of renal function at d 12) Results: Among

37 Placebo-Controlled, Randomized Trial of SOC ± Rituximab For Treatment of AMR 1 Primary endpoint: a composite criterion (graft loss or absence of improvement of renal function at d 12) Results: Among the 38 patients included with AMR, 52.6% (10/19) met the primary endpoint in the rituximab group vs 57.9% (11/19) in the placebo group (P =.744); there were no differences in SCr, proteinuria, and glomerulitis at 1, 6, or 12 mo SCr: serum creatinine. 1. Sautenet B et al American Transplant Congress (ATC 2013). Abstract 226.

38 Desensitization Protocol For +XM 1 FK506 (0.1 mg/kg/d) MMF (2 gm/d) Steroids ATG Anti-CD20 Continue FK506 Continue MMF (2 gm/d) Prednisone Taper Preoperative PP/IVIG TXP Postoperative PP/IVIG Goal Is a ( ) Cyto XM Goal Is a ( ) Flow XM ATG: anti-thymocyte globulin; MMF: mycophenolate mofetil. 1. Montgomery RA. Am J Transplant. 2010;10:

39 AMR in HLA-Incompatible Transplants 1 Type of AMR Incidence (%) Treatment Response Severe oliguric AMR 8.9% Not responsive to PP/IVIg/anti-CD20 AMR 15.8% Responds to PP/IVIg/anti-CD20 No AMR 75.3% No treatment beyond protocol CMR: cell-mediated rejection. 1. Orandi BJ et al. Am J Transplant In press.

40 PP/IVIg Treatment Protocol for Acute AMR 1 Anti-CD20 Steroid bolus or α-thymocyte globulin PP: single plasma volume exchange IVIg: 100 mg/kg following each PP treatment (CMV hyperimmune globulin) PP/IVIg PP/IVIg PP/IVIg PP/IVIg PP/IVIg AMR diagnosis CMV: cytomegalovirus. 1. Montgomery RA et al. Transplantation. 2000;70:

41 Severe Oliguric AMR and the Impact of Rescue Splenectomy 1 1. Locke JE et al. Am J Transplant. 2007;7:

42 Severe Oliguric AMR and the Impact of Rescue Splenectomy 1 1. Locke JE et al. Am J Transplant. 2007;7:

ahus: atypical hemolytic uremic syndrome; DAF: decay-accelerating factor;

43 Classical Complement Pathway in Acute AMR in Sensitized KTRs 1 ECULIZUMAB a a FDA approved for PNH and ahus. ahus: atypical hemolytic uremic syndrome; DAF: decay-accelerating factor; PNH: paroxysmal nocturnal hemoglobinuria; Y-CVF, Yunnan-cobra venom factor. 1. Stegall MD et al. Nat Rev Nephrol. 2012;8:

Treatment Protocol for Severe Oliguric Acute AMR 1,2 Anti-CD20 Steroid bolus or α-thymocyte globulin Heparin D/C FK 506 PP/IVIg AMR diagnosis PP/IVIg PP/IVIg PP/IVIg PP/IVIg 1 2 3 4 Eculizumab

44 Treatment Protocol for Severe Oliguric Acute AMR 1,2 Anti-CD20 Steroid bolus or α-thymocyte globulin Heparin D/C FK 506 PP/IVIg AMR diagnosis PP/IVIg PP/IVIg PP/IVIg PP/IVIg Eculizumab Eculizumab 1,200 mg 600 mg Splenectomy Eculizumab 600 mg Eculizumab 600 mg Eculizumab 600 mg 1. Locke JE et al. Am J Transplant. 2009;9: Iyer HS et al.curr Opin Nephrol Hypertens. 2013;22:

45 Graft Survival After Severe AMR By Intervention 1 1. Orandi BJ et al. Am J Transplant In press.

Transplant Glomerulopathy in Early Severe Oliguric AMR 1 Graft Loss/Died Missing 3 2

46 Transplant Glomerulopathy in Early Severe Oliguric AMR 1 Graft Loss/Died Missing CG: chronic glomerulopathy. 1. Orandi BJ et al. Am J Transplant In press.

47 Prevention Of AMR In Desensitized Patients With Eculizumab 1 PreTx BFXM <300 MESF <19,300 BFXM <200 MESF <10,000 STOP MESF 10, , , , ,200 STOP No post-transplant PP/biopsy/Ab levels at 4, 7, 14, 28, and 90 BFXM: B-cell flow cytometric crossmatch; MESF: molecules of equivalent soluble fluorochrome. 1. Stegall MD et al. Am J Transplant. 2011;11:

48 Prevention Of AMR In Desensitized Patients 1 Category Follow-up (mean mo + SD, range) Eculizumab (n = 26) ( ) Control (n = 51) ( ) Graft survival at 1 y (n, %) 16/16 (100) 49/51 (97) 1.00 AMR 3 mo (n, %) 2 (7.7) 21 (41).0031 Patients developing high DSA levels 3 mo a 13 (50) 22 (43).63 High DSA biopsies C4d+ (n, %) 13 (100) 20 (91).52 High DSA and C4d+ biopsies showing AMR (n, %) P N/A 2 (15) 20 (100) <.0001 Cellular rejection 3 mo (n, %) 1 (6.2) 1 (2).42 a B flow XM channel shift >350 at any time point in the first 3 mo. 1. Stegall MD et al. Am J Transplant. 2011;11:

49 Approaches to the Use of Eculizumab: Hopkins Versus Mayo Approach 1 Hopkins Approach Eculizumab along with PP (and splenectomy) used to rescue kidneys with severe AMR phenotype (8.9% occurs POD 5- POD 7) Rationale 75% of patients will not have AMR; this approach avoids the cost of treating them Protecting the kidney from complement-mediated damage while removing DSA might improve outcomes (reduce risk for immediate graft loss and TG) POD: postoperative day. 1. Courtesy of Robert A. Montgomery, MD, DPhil, FACS. Mayo Approach Eculizumab used as prophylaxis to reduce the incidence (from 41% to 7.7%; P =.003) and severity of early AMR Done without the use of posttransplant PP In some cases, remaining DSA disappears; in others it persists beyond the discontinuation of the agent, with many of these patients developing TG

50 AMR: C1 Esterase Inhibitor a Mechanistically Attractive Due To Proximal Complement Blockade 1 A FDA approved for hereditary angioedema. C1-INH: C1 esterase inhibitor; FDP: fibrin degradation product; HMWK: high molecular weight kininogen; IL: interleukin; KK: kallikrein; MASP: MBP-associated serine protease; MBP: mannosebinding protein; TNF: tumor necrosis factor; tpa: tissue plasminogen activator. 1. Levy J, O Donnell P. Expert Opin Investig Drugs. 2006;15:

51 Conclusions The rate of AMR after desensitization is 24.7%, of which 8.9% is severe and nonresponsive to standard therapy and 15.8% is not graft-threatening and is responsive to PP; both phenotypes at risk for TG Rituximab has an attractive mechanism and, when B-cell precursor rates are high, prevents anamnestic responses; however, this does not seem to translate into efficacy for the prevention or treatment of AMR Splenectomy is effective in rescuing kidneys with the severe AMR phenotype but does not protect against TG A combination of splenectomy, PP/IVIg, and eculizumab is good rescue therapy and appears to prevent TG in the severe AMR phenotype Eculizumab is very effective in reducing the rate of AMR in the first 3 mo after desensitization but, if high levels of DSA persist, there is a likelihood of chronic AMR/TG C1 esterase inhibitor provides more proximal complement blockade, and endogenous levels are depleted by PP

52 Panel Discussion: Review of Clinical Cases Denis Glotz, MD, PhD Saint-Louis Hospital Paris, France Robert A. Montgomery, MD, DPhil, FACS The Johns Hopkins Hospital Baltimore, Maryland

53 Prophylaxis of AMR: F.T.

54 F.T.: Transplant Status Potential living donor: sister Donor Status 4 MM: A24, B35, DR4, DQ8 Positive cytotoxic crossmatch T, IgG F.T. s Status 3 DSAs (MFI >15000): A24, DR4, DQ8

55 Patient Report Cytotox PRA: 93% vpra: 100% 1 donor /5 y

56 Prophylaxis of AMR: Treatment Considerations for F.T. IVIg high dose (Glotz, Jordan) PP/IVIg (Montgomery) acd20/ivig (Jordan) Bortezomib protocols (Woodle)

57 Prophylaxis of AMR: Desensitization Desensitization (1): lower cytotoxicity and obtain a negative cytotoxic crossmatch Desensitization (2): lower MFIs and negativate (as much as possible) the flow crossmatch

58 Prophylaxis of AMR: Desensitization (Cont d) Desensitization (1): lower cytotoxicity and obtain a negative cytotoxic crossmatch 6 monthly cures of IVIg high dose Desensitization (2): lower MFIs and negativate (as much as possible) the flow crossmatch 4 PP/IVIg sessions just before Tx

59 Prophylaxis of AMR Negative cytotoxic and flow crossmatches with low DSAs (<1,500) Transplantation, immediate function But AMR at day 10!

60 TT by C5 Inhibition: LD Tx HD Bx Bx Bx PP IVIg Cy 1. Courtesy of Denis Glotz, MD, PhD.

61 TT by C5 Inhibition: LD Tx (Cont d) 1. Courtesy of Denis Glotz, MD, PhD. Eculizumab

62 Kidney Transplantation Compared With Dialysis: Clinically Relevant Outcomes A systematic review of 110 studies (1,961,904 participants) with kidney failure Key findings Kidney transplantation was associated with» Reduced risk of mortality and cardiovascular events» Improved quality of life (vs chronic dialysis) Benefits of transplant (vs chronic dialysis) increased over time despite increased age and comorbidities of KTRs Results were consistent» For different dialysis modalities» For deceased and living donors» Across countries with differing health care systems Results confirm that kidney transplantation is the preferred modality of treatment for chronic kidney failure 1. Tonelli M et al. Am J Transplant. 2011;11:

63 Preventing AMR in Sensitized Deceased-Donor KTRs 1 Open-label, single-arm, multicenter phase 2 trial: 9-wk preliminary results Primary endpoint: post-transplantation treatment failure rate at wk 9, defined by biopsy-proven AMR, graft loss, patient death, and/or loss to follow-up Ec 1,200 mg Ec 1,200 mg Ec 900 mg Ec 1,200 mg Ec 1,200 mg D 0 D 1, 7, 14, 28 Wk 5 Wk 7 Wk 9 Induction: rabbit ATG EC: eculizumab. Maintenance: prednisone, tacrolimus, mycophenolate 1. Glotz D et al. 16th Congress of the European Society for Organ Transplantation (ESOT 2013). Abstract 2071.

64 Preventing AMR in Sensitized Deceased-Donor KTRs 1 Outcome Post-transplant failure rate Primary composite endpoint including 1) biopsyproven AMR (grade II or III), 2) graft loss, 3) patient death, and 4) loss to follow-up. Eculizumab (N=47) n (%) 5 (10.6); (3.5, 23.1) Biopsy-proven AMR 3 (6.4) Graft loss and/or death 2 (4.3) Lost to follow-up 0 (0) Data from local laboratory instead of the central laboratory 1. Glotz D et al. ESOT Abstract 2071.

66 Thank You and Good Afternoon! Please remember to complete and submit your Post-Test and Evaluation for CME credit. Missed anything? Visit us at Download slides and Practice Aids Watch for the OnDemand version of this symposium PVI, PeerView Institute for Medical Education and University of New Mexico School of Medicine, Office of Continuing Medical Education, are responsible for the selection of this report s topics, the preparation of editorial content, and the distribution of this report. The preparation of PeerView reports is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and University of New Mexico School of Medicine, Office of Continuing Medical Education. Our reports may contain references to unapproved products or uses of these products in certain jurisdictions. For approved prescribing information, please consult the manufacturer's product labeling. No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. Copyright , PeerView Press

Treatment of Chronic Antibody Mediated Rejection

Treatment of Chronic Antibody Mediated Rejection Robert A. Montgomery MD, DPhil Professor of Surgery Director of the NYU Langone Transplant Institute Disclosures: Served on Advisory Boards for Genentech